Precocious and premature puberty associated with treatment of acute lymphoblastic leukaemia

A D LEIPER,* R STANHOPE,† P KITCHING,* AND J M CHESSELS*
*Departments of Haematology and Oncology and †Growth and Development, Hospital for Sick Children, London

SUMMARY  Early puberty in 28 children (23 girls, five boys) treated for acute lymphoblastic leukaemia (ALL) at a mean age of 4·0 years (range 1·4–19·8) is described. All but one had received prophylactic cranial irradiation (1800–2400 cGy) and three children had received additional cranial or craniospinal irradiation as treatment for relapse of their leukaemia. Mean age for the onset of puberty was 8·8 (SD 0·8) years in the girls and 9·3 (0·8) years in the boys; this is greater than two standard deviations from the mean for normal girls and boys. Five children (three girls, two boys) had precocious puberty. The onset of puberty occurred at greater than two standard deviations from the mean for normal girls and boys in 14 (13%) girls and 4 (3%) boys treated at less than eight years of age between 1970 and 1985. In a group of 55 girls treated for ALL who had survived in first remission for six years or more from diagnosis, there was a relation between young age at onset of treatment and early menarche. We suggest that premature activation of the hypothalamic-pituitary-gonadal axis occurs as a consequence of hypothalamic dysfunction due to cranial irradiation. Precocious and premature puberty in children treated for ALL may be an important factor in contributing to short stature.

The outcome for children with acute lymphoblastic leukaemia (ALL) has steadily improved since the introduction of combination chemotherapy and measures to prevent overt leukaemic infiltration of the central nervous system.1 The most common form of prophylaxis to prevent infiltration comprises fractionated cranial irradiation and a course of intrathecal methotrexate. Cranial irradiation commonly causes pituitary dysfunction when given in high doses for treatment of tumours of the central nervous system that are distant from the hypothalamic pituitary region. Growth hormone deficiency,2 delayed puberty,3, 4 and precocious puberty5 6 have been reported. Endocrine morbidity in patients treated for acute ALL with cranial irradiation also occurs but to a lesser degree in those who have received 2400 cGy or less.7 Partial or complete growth hormone deficiency is the commonest form of dysfunction and recently it has been recognised that its occurrence is far more widespread than previously suspected.2 8 Nevertheless, despite the recognition of growth impairment and deviation from expected height centiles in patients with acute ALL,8 9 most children receiving prophylaxis with cranial radiation have standing height measurements within the normal range and probably do not require growth hormone supplements.9 10

We have recently noticed a tendency towards early pubertal development in female survivors of ALL treated with cranial irradiation. A similar finding has been reported by Pasqualini et al (Abstract presented at the Seventh International Congress of Endocrinology, October, 1984). We retrospectively analysed the timing and pattern of sexual maturation in children treated for ALL who presented to this hospital from 1970 to 1985.

Patients and methods

From 1970 to 1985 inclusive, 749 patients with ALL presented to this hospital; 482 were still alive in January 1987. Pubertal maturation was assessed in all current survivors who presented during this period and who were less than eight years old at the start of treatment, who had not received testicular or whole body irradiation, and whose present age was greater than 7 years. Two hundred and thirty three children conformed to these criteria. We analysed the data of 28 of these patients (23 girls, five boys) who had evidence of early (>1·4SD)
pubertal maturation. Twenty three were in first remission and five had one or more relapses. All had normal serum thyroxine and thyroid stimulating hormone concentrations at the time of assessment. One girl had a family history of early puberty. Mean age at initial treatment was 3-8 years (range, 1-4-6-5) in the girls and 4-8 years (range, 2-6-7-8) in the boys.

Between 1970 and 1979 patients were treated on protocols that were devised by or being piloted for the Medical Research Council Working Party on Childhood Leukaemia; these have been described in detail elsewhere. From 1979 onwards patients were treated by protocols devised at the Hospital for Sick Children or by the Medical Research Council Working Party (UKALL X). In 1972 cranial irradiation (2400 cGy in 15 fractions over three weeks) was introduced as prophylaxis against meningeal leukaemic infiltration in conjunction with a course of intrathecal methotrexate. From January 1981 onwards cranial irradiation was reduced to 1800 cGy in 10 fractions over two weeks. One of the 28 patients, a girl diagnosed before 1972, did not receive cranial irradiation after induction but received craniospinal irradiation as treatment for a subsequent relapse in the central nervous system. Relapse and radiation data from the 28 patients compared with the total number of patients treated are shown in the table. Three patients, between 1970 and 1980, received 2000–2200 cGy.

Fifty five girls with ALL treated between 1971 and 1979 attained menarche. All were alive six years or more after diagnosis and had experienced no relapse of their leukaemia. The age at which menarche occurred was recorded in the case notes. Height was measured with a stadiometer by standard anthropometric techniques. Puberty was staged by the method of Tanner. Testicular volume was assessed with an orchidometer. The attainment of stage 2 breast development in girls and a 4 ml testicular volume in boys were used to indicate the onset of puberty. Normal data for the attainment of stages of sexual maturation and menarche were from Marshall and Tanner.

![Fig 1](http://adc.bmj.com/)

Fig 1 Age at onset of puberty of 28 children treated for ALL at a mean age of 4-0 years (range 1-4-7-8) compared with normal values.

### Table  Data of 28 children with evidence of early pubertal maturation

<table>
<thead>
<tr>
<th>Sex of child</th>
<th>No with early puberty (total No assessed*)</th>
<th>Type of relapse (n=5)</th>
<th>Radiation dose (cGy)</th>
<th>Site of irradiation (No of patients)</th>
</tr>
</thead>
<tbody>
<tr>
<td>First remission</td>
<td>15 girls</td>
<td>18(132)</td>
<td>Bone marrow (4)</td>
<td>2400 2000–2200 Cranial (15)</td>
</tr>
<tr>
<td></td>
<td>3 boys</td>
<td>4(21)</td>
<td></td>
<td>2400 Cranial (3)</td>
</tr>
<tr>
<td></td>
<td>4 girls</td>
<td>4(21)</td>
<td></td>
<td>1800 Cranial (2)</td>
</tr>
<tr>
<td>Relapses</td>
<td>Total</td>
<td>22(153)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>1970–80</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1981–85</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First remission</td>
<td>3 girls</td>
<td>5(72)</td>
<td>Central nervous system (1)</td>
<td>2400 Cranial (1)</td>
</tr>
<tr>
<td></td>
<td>2 boys</td>
<td>5(72)</td>
<td></td>
<td>1800 Cranial (4)</td>
</tr>
<tr>
<td>Relapses</td>
<td>Total</td>
<td>6(80)</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

*Less than 8 years old at start of treatment.
Precocious and premature puberty associated with treatment of acute lymphoblastic leukaemia

Fourteen patients (11 girls, three boys) had computed tomograms taken of the brain by either a Toshiba TCT 60 scanner with hypothalamic pituitary reconstructions or an EMI scanner. Mean timing of the first scan from the onset of prophylactic central nervous system irradiation was 2.75 years (range 0.1–11.0); five patients had brain scans before one year from the onset of central nervous system irradiation. Nine patients had serial computed tomograms taken, up to a maximum of four scans.

Results

Fig 1 shows the age of onset of puberty in the 28 patients compared with data from normal children; three girls and two boys had precocious puberty (signs of sexual maturation occurring before 8 years in girls and 9 years in boys. Mean age for the onset of puberty was 8.8 (SD 0.8) years in the girls and 9.3 (0.8) years in the boys. Mean age for the onset of puberty in these 28 patients was greater than two standard deviations from the mean for normal girls.

Fig 2  Growth data from seven girls treated for ALL whose growth had been, or almost been, completed. None had received spinal irradiation. Onset of the growth spurt is compared with normal values for British children.
and boys.\textsuperscript{18} The onset of puberty in patients treated during the years 1970–80 occurred at more than two standard deviations from the mean for normal girls and boys in 10 girls (14\%) and three boys (4\%). The onset of puberty in patients treated during the years 1981–5 occurred at more than two standard deviations from the mean for normal girls and boys in four girls (12\%) and one boy (2\%). In both treatment periods, 1970–80 and 1981–85, the number of girls entering puberty before two standard deviations from the mean was much greater than the 3\% one would have expected in the normal population. Equivalent data for the boys were not significant. The ratio of girls to boys entering puberty at more than two standard deviations from the mean was 4:1. Unfortunately we do not have data on the timing of the onset of puberty in all patients included in this study. The onset of puberty was only accurately assessed when early sexual maturation was noticed and so our figures probably underestimate the true incidence of early puberty.

Fig 2 shows the growth of seven girls from this group where final height had been, or had almost been, achieved. The early onset of the growth acceleration can be seen when compared with the normal of Tanner \textit{et al.}\textsuperscript{20} Four patients had final heights equal to or less than the third centile but their growth hormone state and epiphyseal maturation had not been assessed, and no conclusion can be drawn from these data about the effect of early puberty on growth prognosis.

None of the computed tomograms showed evidence of hydrocephalus, and the ventricular size in patients who had serial scans did not change. One girl had diffuse cerebral changes that were probably due to methotrexate encephalopathy. Another girl had an empty sella; this has been associated with irradiation damage.\textsuperscript{21}

Data relating age of onset of treatment of 55 girls with age at menarche are shown in fig 3. The younger the age at diagnosis (equivalent to age at the start of treatment) the earlier menarche occurred ($r=0.53$, $p<0.001$).

**Discussion**

Our data suggest that treatment of ALL is associated with the development of premature puberty, and, in a significant proportion of children, precocious puberty. Our patients retained the harmony of the sequence of acquisition of secondary sexual characteristics and the relation of these to the growth spurt that is characteristic of normal puberty.\textsuperscript{22} Therefore, premature and precocious puberty in our patients was likely to be central (gonadotrophin dependent) in origin, although we do not have endocrinological data. The onset of pubertal development was related to the age of onset of treatment. This parallels the finding that young children are more susceptible to growth hormone insufficiency after prophylaxis with cranial irradiation in the treatment of ALL.\textsuperscript{23}

Cranial irradiation has been reported to cause central precocious puberty in both the treatment of brain tumours in doses greater than 3300 cGy and in one girl with ALL when the dose of irradiation was only 2400 cGy;\textsuperscript{6} this girl, however, also received intrathecal methotrexate. In our patients premature puberty was associated with doses of cranial irradiation as low as 1800 cGy. The incidence of early puberty was slightly higher in the group of patients diagnosed between 1970 and 1980. This is likely to reflect the greater proportion of children of adolescent age, but the lower dosage of 1800 cGy of cranial irradiation introduced in 1981 may also have bearing on this observation. Only greater numbers and a longer follow up will elucidate this further. Damage to the hypothalamic-pituitary axis can
cause abnormal secretion of gonadotrophin releasing hormone and be associated with either precocious or delayed puberty. The change in hypothalamic function that we have seen was probably caused by irradiation rather than intrathecal chemotherapy and like other endocrine effects of irradiation seems to have been delayed. We found no evidence of hydrocephalus occurring as a consequence of cranial irradiation in the regimen that we used.

There was a four fold preponderance of girls with early puberty that was not accounted for by superior survival of girls over boys. In this study, when all criteria for inclusion were met, there were roughly equal numbers of boys and girls. There is a sex difference in the response to gonadotrophin releasing hormone and its analogues that may be relevant to this observation. In delayed puberty induced by pulsatile administration of gonadotrophin releasing hormone girls require lower doses than boys to maintain equivalent progress in sexual maturation. By contrast, in the suppression of central precocious puberty, girls require larger doses of gonadotrophin releasing hormone analogue than boys.

The growth of children with central precocious puberty is compromised by rapid epiphyseal maturation that ultimately limits growth. It may well be that premature puberty, such as we have described, may cause a similar phenomenon. There are many other factors, however, such as growth hormone insufficiency, which are pertinent to the growth of children with treated ALL especially those who have been retreated after a relapse. The impairment in growth caused by growth hormone insufficiency or spinal irradiation, or both, is probably masked by the early growth spurt associated with precocious or premature puberty. The net result would be a relatively normal growth velocity but with rapid advancement in epiphyseal maturation causing a reduction in adult height potential. Without regular anthropometric measurements, including sitting height and accurate assessment of epiphyseal maturation, such an effect on growth could be misinterpreted.

We believe that the recognition of premature sexual development in children with ALL may be important both for psychological and anthropometric reasons. Although cyproterone acetate and probably gonadotrophin releasing hormone analogues do not affect the final prediction of height of children with central precocious puberty, both agents suppress sexual maturation. We agree with the suggestion of Brauner and Rappaport that a combined approach with a gonadotrophin releasing hormone analogue and human growth hormone may therefore provide the best anthropometric response.

Shalet has discussed the role of endocrine deficiency and spinal growth in the impairment of the growth of children with treated ALL. We wish to add to the list premature and precocious puberty as important additional sequelae.

We are grateful to Professor MA Precece, Institute of Child Health, London, for his helpful criticism of the manuscript.

References
20. Tanner JM, Whitehouse RH, Takaiishi M. Standards from birth to maturity for height, weight, height velocity and weight
Leiper, Stanhope, Kitching, and Chessells


Correspondence to Dr R Stanhope, Department of Growth and Development, Institute of Child Health, 30 Guilford Street, London WC1N 1EH.

Received 29 June 1987
Precocious and premature puberty associated with treatment of acute lymphoblastic leukaemia.
A D Leiper, R Stanhope, P Kitching and J M Chessells

Arch Dis Child 1987 62: 1107-1112
doi: 10.1136/adc.62.11.1107

Updated information and services can be found at:
http://adc.bmj.com/content/62/11/1107

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/